Neurofilament light polypeptide

"NEFL" redirects here. For the basketball team formerly known as Nueva Ecija ForestLake, see Nueva Ecija Rice Vanguards.

Neurofilament light polypeptide is a protein that in humans is encoded by the NEFL gene.[5]

Structure

Neurofilament light polypeptide is a member of the intermediate filament protein family. This protein family consists of over 50 human proteins divided into 5 major classes, the Class I and II keratins, Class III vimentin, GFAP, desmin and the others, the Class IV neurofilaments and the Class V nuclear lamins. There are four major neurofilament subunits, NF-L, NF-M, NF-H and α-internexin. These form heteropolymers which assemble to produce 10 nm neurofilaments which are only expressed in neurons where they are major structural proteins, particularly concentrated in large projection axons. The NF-L protein is encoded by the NEFL gene.[6][5]

Function

These neurofilament heteropolymers assemble into the cytoskeleton of axons, where they provide structural support and help regulate axonal diameter and conduction velocity. Axons are particularly sensitive to mechanical and metabolic compromise and as a result axonal degeneration is a significant problem in many neurological disorders. Neurofilament light chain is a biomarker that can be measured with immunoassays in cerebrospinal fluid and plasma and reflects axonal damage in a wide variety of neurological disorders.[7]

Measurement

NF-L antibodies employed in the most widely used NF-L assays are specific for cleaved forms of NF-L generated by proteolysis induced by cell death.[8] Methods used in different studies for NfL measurement are sandwich enzyme-linked immunosorbent assay (ELISA), electrochemiluminescence, and high-sensitive single molecule array (SIMOA).[9]

Clinical significance

The detection of neurofilament subunits in CSF and blood has become widely used as a biomarker of ongoing axonal compromise. It is a useful marker for disease monitoring in amyotrophic lateral sclerosis,[10] multiple sclerosis,[11] Alzheimer's disease,[12][13] and more recently Huntington's disease.[14] It is also a promising marker for follow-up of patients with brain tumors.[15] Higher levels of blood or CSF NF-L have been associated with increased mortality, as would be expected as release of this protein reflects ongoing axonal loss.[16]

It is associated with Charcot–Marie–Tooth disease 1F and 2E.[6]

Neurofilament assembly

Rat brain cells grown in tissue culture and stained, in green, with an antibody to neurofilament subunit NF-L, which reveals a large neuron. The culture was stained in red for α-internexin, which in this culture is found in neuronal stem cells surrounding the large neuron.
A formalin-fixed and paraffin-embedded section of the human cerebellum is stained with an antibody specific to NF-L, visualized with a brown dye. Cell nuclei are counterstained with a blue dye. The nucleus-rich region on the left side corresponds to the granular layer, while the region on the right represents the molecular layer. The antibody binds to the processes of basket cells, the parallel fiber axons, the perikarya (cell bodies) of Purkinje cells, and various other axons.

Neurofilament light polypeptide (NF-L) is a key structural component of the neuronal cytoskeleton, assembling into neurofilaments along with other intermediate filament proteins such as NF-M, NF-H, and α-internexin.[17][18] These proteins form obligate heteropolymers that organize into 10 nm diameter filaments,[17][18] which are selectively expressed in neurons and are particularly concentrated in axons[9]. Neurofilaments provide essential structural support, help maintain axonal diameter,[19][18] and contribute to the efficient conduction of nerve impulses.[19]

The localization and organization of NF-L in neurons can be visualized using immunohistochemical techniques. In tissue culture preparations of rat brain cells, antibodies specific to NF-L label large neurons prominently in green, revealing their extensive cytoskeletal architecture.[20] In the same cultures, staining for α-internexin in red highlights surrounding neuronal stem cells, indicating the differential expression of these intermediate filament proteins during neural development and differentiation.[18]

In histological sections of human brain tissue, NF-L can also be visualized using immunostaining. For example, in formalin-fixed and paraffin-embedded sections of the human cerebellum, an antibody specific to NF-L reveals its presence throughout various neuronal compartments[7]. The brown-stained antibody binding highlights the axonal processes of basket cells, the parallel fibers of granule cells,[21][18] the perikarya of Purkinje cells,[21] and other axonal elements. Counterstaining with a blue dye allows for the visualization of cell nuclei, delineating the granular layer on the left side of the section and the molecular layer on the right.[21] These staining patterns underscore the widespread and structurally critical role of NF-L in both developing and mature neurons.[19][18]

Interactions

Neurofilament light polypeptide has been shown to interact with:

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000277586 – Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000022055 – Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ a b "Entrez Gene: NEFL neurofilament, light polypeptide 68kDa".
  6. ^ a b Miltenberger-Miltenyi G, Janecke AR, Wanschitz JV, Timmerman V, Windpassinger C, Auer-Grumbach M, et al. (July 2007). "Clinical and electrophysiological features in Charcot-Marie-Tooth disease with mutations in the NEFL gene". Archives of Neurology. 64 (7): 966–970. doi:10.1001/archneur.64.7.966. PMID 17620486.
  7. ^ Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, et al. (October 2018). "Neurofilaments as biomarkers in neurological disorders". Nature Reviews. Neurology. 14 (10): 577–589. doi:10.1038/s41582-018-0058-z. PMID 30171200. S2CID 52140127. neuroaxonal damage is the pathological substrate of permanent disability in various neurological disorders .... Here, we review what is known about the structure and function of neurofilaments, discuss analytical aspects and knowledge of age-dependent normal ranges of neurofilaments and provide a comprehensive overview of studies on neurofilament light chain as a marker of axonal injury in different neurological disorders, including multiple sclerosis, neurodegenerative dementia, stroke, traumatic brain injury, amyotrophic lateral sclerosis and Parkinson disease.
  8. ^ Shaw G, Madorsky I, Li Y, Wang Y, Jorgensen M, Rana S, et al. (2023-03-02). "Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration". Brain Communications. 5 (2): fcad067. doi:10.1093/braincomms/fcad067. PMC 10120172. PMID 37091583.
  9. ^ Arslan B, Ayhan Arslan G, Tuncer A, Karabudak R, Sepici Dinçel A (September 2022). "Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective". Bosnian Journal of Basic Medical Sciences. 22 (5): 699–706. doi:10.17305/bjbms.2021.7326. PMC 9519158. PMID 35490364.
  10. ^ Xu Z, Henderson RD, David M, McCombe PA (2016). "Neurofilaments as Biomarkers for Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis". PLOS ONE. 11 (10): e0164625. Bibcode:2016PLoSO..1164625X. doi:10.1371/journal.pone.0164625. PMC 5061412. PMID 27732645. NF heavy and light chain levels have potential use as a marker of neural degeneration in ALS, but are not specific for the disease, and are more likely to be used as measures of disease progression.
  11. ^ Cai L, Huang J (2018). "Neurofilament light chain as a biological marker for multiple sclerosis: a meta-analysis study". Neuropsychiatric Disease and Treatment. 14: 2241–2254. doi:10.2147/NDT.S173280. PMC 6126505. PMID 30214214. NFL chain has significantly increased in MS patients, which substantially strengthens the clinical evidence of the NFL in MS. The NFL may be used as a prognostic biomarker to monitor disease progression, disease activity, and treatment efficacy in the future.
  12. ^ Zetterberg H, Schott JM (February 2019). "Biomarkers for Alzheimer's disease beyond amyloid and tau". Nature Medicine. 25 (2): 201–203. doi:10.1038/s41591-019-0348-z. PMID 30728536. S2CID 59607046.
  13. ^ Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. (February 2019). "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease". Nature Medicine. 25 (2): 277–283. doi:10.1038/s41591-018-0304-3. PMC 6367005. PMID 30664784.
  14. ^ Niemelä V, Landtblom AM, Blennow K, Sundblom J (27 February 2017). "Tau or neurofilament light-Which is the more suitable biomarker for Huntington's disease?". PLOS ONE. 12 (2): e0172762. Bibcode:2017PLoSO..1272762N. doi:10.1371/journal.pone.0172762. PMC 5328385. PMID 28241046.
  15. ^ Arslan B, Ayhan Arslan G, Tuncer A, Karabudak R, Sepici Dinçel A (April 2022). "Evaluation of cerebrospinal fluid neurofilament light chain levels in multiple sclerosis and non-demyelinating diseases of the central nervous system: clinical and biochemical perspective". Bosnian Journal of Basic Medical Sciences. 22 (5): 699–706. doi:10.17305/bjbms.2021.7326. PMC 9519158. PMID 35490364. S2CID 248478048.
  16. ^ Kaeser SA, Lehallier B, Thinggaard M, Häsler LM, Apel A, Bergmann C, et al. (February 2021). "A neuronal blood marker is associated with mortality in old age". Nature Aging. 1 (2): 218–225. doi:10.1038/s43587-021-00028-4. PMID 37118632. S2CID 234008316.
  17. ^ a b Yuan A, Rao MV, Veeranna, Nixon RA (April 2017). "Neurofilaments and Neurofilament Proteins in Health and Disease". Cold Spring Harbor Perspectives in Biology. 9 (4). doi:10.1101/cshperspect.a018309. PMC 5378049. PMID 28373358.
  18. ^ a b c d e f Martens H (2025). "Neurofilaments". Synaptic Systems GmbH.
  19. ^ a b c Yuan A, Rao MV, Veeranna, Nixon RA (July 2012). "Neurofilaments at a glance". Journal of Cell Science. 125 (Pt 14): 3257–63. doi:10.1242/jcs.104729. PMC 3516374. PMID 22956720.
  20. ^ Shaw G, Madorsky I, Li Y, Wang Y, Jorgensen M, Rana S, et al. (2023). "Uman-type neurofilament light antibodies are effective reagents for the imaging of neurodegeneration". Brain Communications. 5 (2): fcad067. doi:10.1093/braincomms/fcad067. PMC 10120172. PMID 37091583.
  21. ^ a b c van der Heijden ME, Sillitoe RV (May 2021). "Interactions Between Purkinje Cells and Granule Cells Coordinate the Development of Functional Cerebellar Circuits". Neuroscience. 462: 4–21. doi:10.1016/j.neuroscience.2020.06.010. PMC 7736359. PMID 32554107.
  22. ^ Frappier T, Stetzkowski-Marden F, Pradel LA (April 1991). "Interaction domains of neurofilament light chain and brain spectrin". The Biochemical Journal. 275 (2): 521–527. doi:10.1042/bj2750521. PMC 1150082. PMID 1902666.
  23. ^ Mukai H, Toshimori M, Shibata H, Kitagawa M, Shimakawa M, Miyahara M, et al. (April 1996). "PKN associates and phosphorylates the head-rod domain of neurofilament protein". The Journal of Biological Chemistry. 271 (16): 9816–9822. doi:10.1074/jbc.271.16.9816. PMID 8621664.
  24. ^ Haddad LA, Smith N, Bowser M, Niida Y, Murthy V, Gonzalez-Agosti C, et al. (November 2002). "The TSC1 tumor suppressor hamartin interacts with neurofilament-L and possibly functions as a novel integrator of the neuronal cytoskeleton". The Journal of Biological Chemistry. 277 (46): 44180–44186. doi:10.1074/jbc.M207211200. PMID 12226091.

Further reading